Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Kopetz S, Bekaii-Saab T, Yoshino T, Chung C-H, Zhang X, Tabernero J June 4, 2022 ASCO 2022 Colorectal Cancer

SEAMARK: Randomized Phase 2 Study of Pembrolizumab + Encorafenib + Cetuximab vs Pembrolizumab Alone for First-Line Treatment of BRAF V600E-Mutant Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Metastatic Colorectal Cancer (mCRC)

View Presentation View Abstract Plain Language Summary
Poster
Ng K, Ciardiello F, Van Cutsem E, Yaeger R, Yoshino T, Desai J, Wasan HS, Alkuzweny B, Zhang X, Tabernero J, Kopetz S July 2, 2022 ESMO World GI 2022 Colorectal Cancer

Evaluating Age as a Factor for Survival and Quality of Life in Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer Treated With Encorafenib + Cetuximab ± Binimetinib: Subanalysis of BEACON CRC

View Presentation
Oral Presentation
Tabernero J, Yoshino T, Kim TW, Yaeger R, Desai J, Wasan HS, Van Cutsem E, Ciardiello F, Maughan T, Eng C, Tie J, Elez E, Lonardi S, Zhang X, Chavira R, Usari T, Hahn E, Kopetz S September 12, 2022 ESMO 2022 Colorectal Cancer

BREAKWATER Safety Lead-In (SLI): Encorafenib (E) + Cetuximab (C) + Chemotherapy (Chemo) for BRAFV600E Metastatic Colorectal Cancer (mCRC)

View Presentation View Abstract Plain Language Summary
Oral Presentation
Kopetz S, Murphy DA, Pu J, Yaeger R, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Alkuzweny B, Xie T, Zhang X, Tabernero J September 12, 2022 ESMO 2022 Colorectal Cancer

Genomic Mechanisms of Acquired Resistance of Patients (pts) With BRAF V600E-Mutant (mt) Metastatic Colorectal Cancer (mCRC) Treated in the BEACON Study

View Presentation View Abstract Plain Language Summary
Poster
Kopetz S, Yoshino T, Kim TW, Yaeger R, Desai J, Wasan H, Van Cutsem E, Ciardiello F, Maughan T, Eng C, Tie J, Elez E, Lonardi S, Zhang X, Chung C-H, Usari T, Nichols T, Murphy D, Tabernero J January 21, 2023 ASCO GI 2023 Colorectal Cancer

BREAKWATER Safety Lead-in (SLI): Encorafenib (E) + Cetuximab (C) + Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC)

View Presentation
Poster
Wilson R, Vieira MC, Roach M, Prood N, Mesana L, Belani A, May SG January 21, 2023 ASCO GI 2023 Colorectal Cancer

Patient Perspectives on Colorectal Cancer Care Delivery During the COVID-19 Pandemic: A Qualitative Interview Study

View Presentation
Poster
Kopetz S, Bekaii-Saab T, Yoshino T, Chung C-H, Zhang X, Tabernero J January 21, 2023 ASCO GI 2023 Colorectal Cancer

SEAMARK: Randomized Phase 2 Study of Pembrolizumab + Encorafenib + Cetuximab vs Pembrolizumab Alone for First-Line Treatment of BRAF V600E-Mutant Microsatellite Instability-High (MSI-H)/Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer (mCRC)

View Presentation View Abstract Plain Language Summary